Factors for graft-versus-host disease after donor lymphocyte infusions with an escalating dose regimen:: lack of association with cell dose
Factors for graft-versus-host disease after donor lymphocyte infusions with an escalating dose regimen:: lack of association with cell dose
复制标题
DOI：
10.1111/j.1365-2141.2007.06501.x
复制
发表时间：
2007-03-01
影响因子：
6.5
通讯作者：
Dazzi, F.
中科院分区：
文献类型：
--
作者：
Fozza, C.;Szydlo, R. M.;Dazzi, F.
我们使用慢性粒细胞性白血病的慢性淋巴细胞治疗（DLI）研究了82例接受供体淋巴细胞输注（DLI）治疗的患者中，慢性髓样白血病在常规同种异体后，我们调查了82例接受供体淋巴细胞输注（DLI）的患者的危险因素。出现了两个因素作为急性和慢性GVHD的预测因素：女性捐助者对淋巴细胞的输注以及移植和最后DLI之间的间隔，但在多变量分析中只有第一个显着。令人惊讶的是，淋巴细胞剂量不影响GVHD的发生率。我们的结果表明，DLI可以以大细胞剂量给予，而不会增加GVHD的风险。
We investigated the risk factors for graft-versus-host disease (GVHD) in 82 patients treated with donor lymphocyte infusions (DLI) using an escalating dose regimen for chronic myeloid leukaemia in relapse following conventional allografting. Two factors emerged as predictors of both acute and chronic GVHD: the infusion of male recipients with lymphocytes from a female donor and the interval between transplant and last DLI, but only the first remained significant at multivariate analysis. Surprisingly, lymphocyte dose did not influence the incidence of GVHD. Our results suggest that DLI can be given in large cell doses without increasing the risk of GVHD.